31 results on '"O’Doherty, Una"'
Search Results
2. Rapid manufacturing of non-activated potent CAR T cells.
- Author
-
Ghassemi, Saba, Durgin, Joseph S., Nunez-Cruz, Selene, Patel, Jai, Leferovich, John, Pinzone, Marilia, Shen, Feng, Cummins, Katherine D., Plesa, Gabriela, Cantu, Vito Adrian, Reddy, Shantan, Bushman, Frederic D., Gill, Saar I., O'Doherty, Una, O'Connor, Roddy S., and Milone, Michael C.
- Published
- 2022
- Full Text
- View/download PDF
3. Rapid prediction of stem cell mobilization using volume and conductivity data from automated hematology analyzers.
- Author
-
Villa, Carlos H., Porturas, Thomas, Sell, Mary, Wall, Mark, DeLeo, Gene, Fetters, Jenna, Mignono, Sam, Irwin, Leah, Hwang, Wei‐Ting, O'Doherty, Una, Hwang, Wei-Ting, and O'Doherty, Una
- Subjects
HEMATOLOGY ,BLOOD transfusion reaction ,BLOOD group incompatibility ,BLOOD transfusion ,BLOOD testing ,HISTOCOMPATIBILITY ,SAFETY ,CELL motility ,ANALYTICAL chemistry techniques ,FLOW cytometry ,HEMATOPOIETIC stem cells ,RESEARCH funding ,MULTIPLE regression analysis - Abstract
Background: Rapid analytics to predict circulating hematopoietic stem cells are valuable for optimal management of mobilization, particularly for the use of newer and costly mobilization agents such as plerixafor.Study Design and Methods: We used stepwise, linear multiple regression modeling applied to cell population data collected by routine hematology analyzers (Beckman Coulter DxH 800) on patients undergoing autologous stem cell collection (n = 131). Beta coefficients were used to derive a formula for a stem cell index (SCI). We then tested the correlation of SCI with stem cell counts and performance of the SCI as a predictor of poor mobilization with external validation in a separate cohort (n = 183).Results: The SCI correlated strongly with CD34 counts by flow cytometry (r = 0.8372 in the development cohort, r = 0.8332 in the external validation cohort) and compares favorably with other rapid stem cell enumerating technologies. In the external validation cohort, the SCI performed well as a predictor (receiver operating characteristic area under the curve, 0.9336) of poor mobilization (CD34 count < 10), with a sensitivity of 72% and a specificity of 93%. When prevalence of poor mobilization was 33%, this resulted in a positive predictive value of 83% and a negative predictive value of 87%. The SCI also showed promise in tracking responses to plerixafor administration.Conclusion: The findings demonstrate the utility of the cell population data collected by hematology analyzers to provide rapid data beyond standard complete blood counts, particularly for stem cell count prediction, requiring no additional reagents, specimen, or instrumentation. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
4. HLA-C downregulation by HIV-1 adapts to host HLA genotype.
- Author
-
Bachtel, Nathaniel D., Umviligihozo, Gisele, Pickering, Suzanne, Mota, Talia, Liang, Hua, Del Prete, Gregory Q., Chatterjee, Pramita, Lee, Guinevere Q., Thomas, Rasmi, Brockman, Mark A., Neil, Stuart, Carrington, Mary, Bwana, Bosco, Bangsberg, David R., Martin, Jeffrey N., Kallas, Esper G., Donini, Camila Sunaitis, Cerqueira, Natalia B., O’Doherty, Una T., and Hahn, Beatrice H.
- Subjects
HLA histocompatibility antigens ,MEMBRANE proteins ,GENOTYPES ,VIRAL replication ,HIV infections - Abstract
HIV-1 can downregulate HLA-C on infected cells, using the viral protein Vpu, and the magnitude of this downregulation varies widely between primary HIV-1 variants. The selection pressures that result in viral downregulation of HLA-C in some individuals, but preservation of surface HLA-C in others are not clear. To better understand viral immune evasion targeting HLA-C, we have characterized HLA-C downregulation by a range of primary HIV-1 viruses. 128 replication competent viral isolates from 19 individuals with effective anti-retroviral therapy, show that a substantial minority of individuals harbor latent reservoir virus which strongly downregulates HLA-C. Untreated infections display no change in HLA-C downregulation during the first 6 months of infection, but variation between viral quasispecies can be detected in chronic infection. Vpu molecules cloned from plasma of 195 treatment naïve individuals in chronic infection demonstrate that downregulation of HLA-C adapts to host HLA genotype. HLA-C alleles differ in the pressure they exert for downregulation, and individuals with higher levels of HLA-C expression favor greater viral downregulation of HLA-C. Studies of primary and mutant molecules identify 5 residues in the transmembrane region of Vpu, and 4 residues in the transmembrane domain of HLA-C, which determine interactions between Vpu and HLA. The observed adaptation of Vpu-mediated downregulation to host genotype indicates that HLA-C alleles differ in likelihood of mediating a CTL response that is subverted by viral downregulation, and that preservation of HLA-C expression is favored in the absence of these responses. Finding that latent reservoir viruses can downregulate HLA-C could have implications for HIV-1 cure therapy approaches in some individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. A NOT-SO-STABLE RESERVOIR: HIV DRIVES INFECTED CELLS TO DIE AND DIVIDE.
- Author
-
Weissman, Sam, Pinzone, Marilia, Oceguera, Alfonso, Ginda, Ashley, Swiggard, Liam, Cannon, Lamont, Zurakowski, Ryan, and O'Doherty, Una
- Published
- 2023
6. Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials.
- Author
-
Mexas, Angela M., Graf, Erin H., Pace, Matthew J., Yu, Jianqing J., Papasavvas, Emmanouil, Azzoni, Livio, Busch, Michael P., Di Mascio, Michele, Foulkes, Andrea S., Migueles, Stephen A., Montaner, Luis J., O’Doherty, Una, and O'Doherty, Una
- Published
- 2012
- Full Text
- View/download PDF
7. Defective HIV-1 proviruses produce novel proteincoding RNA species in HIV-infected patients on combination antiretroviral therapy.
- Author
-
Imamichi, Hiromi, Dewar, Robin L., Adelsberger, Joseph W., Rehm, Catherine A., O'Doherty, Una, Paxinos, Ellen E., Fauci, Anthony S., and Lane, H. Clifford
- Subjects
HIV infections ,THERAPEUTICS ,HIGHLY active antiretroviral therapy ,HIV-positive persons ,DRUG activation ,CHIMERIC proteins - Abstract
Despite years of plasma HIV-RNA levels <40 copies per milliliter during combination antiretroviral therapy (cART), the majority of HIV-infected patients exhibit persistent seropositivity to HIV-1 and evidence of immune activation. These patients also show persistence of proviruses of HIV-1 in circulating peripheral blood mononuclear cells. Many of these proviruses have been characterized as defective and thus thought to contribute little to HIV-1 pathogenesis. By combining 5'LTR-to-3'LTR single-genome amplification and direct amplicon sequencing, we have identified the presence of "defective" proviruses capable of transcribing novel unspliced HIV-RNA (usHIV-RNA) species in patients at all stages of HIV-1 infection. Although these novel usHIV-RNA transcripts had exon structures that were different from those of the known spliced HIV-RNA variants, they maintained translationally competent ORFs, involving elements of gag, pol, env, rev, and nef to encode a series of novel HIV-1 chimeric proteins. These novel usHIV-RNAs were detected in five of five patients, including four of four patients with prolonged viral suppression of HIV-RNA levels <40 copies per milliliter for more than 6 y. Our findings suggest that the persistent defective proviruses of HIV-1 are not "silent," but rather may contribute to HIV-1 pathogenesis by stimulating host-defense pathways that target foreign nucleic acids and proteins. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy.
- Author
-
Lee, Sulggi A., Bacchetti, Peter, Chomont, Nicolas, Fromentin, Remi, Lewin, Sharon R., O’Doherty, Una, Palmer, Sarah, Richman, Douglas D., Siliciano, Janet D., Yukl, Steven A., Deeks, Steven G., and Burbelo, Peter D.
- Subjects
HIV antibodies ,HIGHLY active antiretroviral therapy ,LUCIFERASES ,IMMUNOPRECIPITATION ,ANTIBODY formation - Abstract
Background: A major challenge to HIV eradication strategies is the lack of an accurate measurement of the total burden of replication-competent HIV (the “reservoir”). We assessed the association of anti-HIV antibody responses and the estimated size of the reservoir during antiretroviral therapy (ART). Methods: We evaluated anti-HIV antibody profiles using luciferase immunoprecipitation systems (LIPS) assay in relation to several blood-based HIV reservoir measures: total and 2-LTR DNA (rtPCR or droplet digital PCR); integrated DNA (Alu PCR); unspliced RNA (rtPCR), multiply-spliced RNA (TILDA), residual plasma HIV RNA (single copy PCR), and replication-competent virus (outgrowth assay). We also assessed total HIV DNA and RNA in gut-associated lymphoid tissue (rtPCR). Spearman correlations and linear regressions were performed using log-transformed blood- or tissue-based reservoir measurements as predictors and log-transformed antibody levels as outcome variables. Results: Among 51 chronically HIV-infected ART-suppressed participants (median age = 57, nadir CD4+ count = 196 cells/mm3, ART duration = 9 years), the most statistically significant associations were between antibody responses to integrase and HIV RNA in gut-associated lymphoid tissue (1.17 fold-increase per two-fold RNA increase, P = 0.004) and between antibody responses to matrix and integrated HIV DNA in resting CD4+ T cells (0.35 fold-decrease per two-fold DNA increase, P = 0.003). However, these associations were not statistically significant after a stringent Bonferroni-adjustment of P<0.00045. Multivariate models including age and duration of ART did not markedly alter results. Conclusions: Our findings suggest that anti-HIV antibody responses may reflect the size of the HIV reservoir during chronic treated HIV disease, possibly via antigen recognition in reservoir sites. Larger, prospective studies are needed to validate the utility of antibody levels as a measure of the total body burden of HIV during treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells.
- Author
-
Cockerham, Leslie R., Siliciano, Janet D., Sinclair, Elizabeth, O'Doherty, Una, Palmer, Sarah, Yukl, Steven A., Strain, Matt C., Chomont, Nicolas, Hecht, Frederick M., Siliciano, Robert F., Richman, Douglas D., and Deeks, Steven G.
- Subjects
T cells ,HIV infections ,ANTIRETROVIRAL agents ,IMMUNE system ,BIOMARKERS - Abstract
The association between the host immune environment and the size of the HIV reservoir during effective antiretroviral therapy is not clear. Progress has also been limited by the lack of a well-accepted assay for quantifying HIV during therapy. We examined the association between multiple measurements of HIV and T cell activation (as defined by markers including CD38, HLA-DR, CCR5 and PD-1) in 30 antiretroviral-treated HIV-infected adults. We found a consistent association between the frequency of CD4
+ and CD8+ T cells expressing HLA-DR and the frequency of resting CD4+ T cells containing HIV DNA. This study highlights the need to further examine this relationship and to better characterize the biology of markers commonly used in HIV studies. These results may also have implications for reactivation strategies. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
10. Quantification of Integrated HIV DNA by Repetitive-Sampling Alu-HIV PCR on the Basis of Poisson Statistics.
- Author
-
De Spiegelaere, Ward, Malatinkova, Eva, Lynch, Lindsay, Van Nieuwerburgh, Filip, Messiaen, Peter, O'Doherty, Una, and Vandekerckhove, Linos
- Published
- 2014
- Full Text
- View/download PDF
11. Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers.
- Author
-
Hatano, Hiroyu, Yukl, Steven A., Ferre, April L., Graf, Erin H., Somsouk, Ma, Sinclair, Elizabeth, Abdel-Mohsen, Mohamed, Liegler, Teri, Harvill, Kara, Hoh, Rebecca, Palmer, Sarah, Bacchetti, Peter, Hunt, Peter W., Martin, Jeffrey N., McCune, Joseph M., Tracy, Russell P., Busch, Michael P., O'Doherty, Una, Shacklett, Barbara L., and Wong, Joseph K.
- Subjects
HIV infections ,THERAPEUTICS ,VACCINES ,ATHEROSCLEROSIS ,BLOOD plasma ,RNA ,T cells ,PHYSIOLOGY - Abstract
The study of HIV-infected “controllers” who are able to maintain low levels of plasma HIV RNA in the absence of antiretroviral therapy (ART) may provide insights for HIV cure and vaccine strategies. Despite maintaining very low levels of plasma viremia, controllers have elevated immune activation and accelerated atherosclerosis. However, the degree to which low-level replication contributes to these phenomena is not known. Sixteen asymptomatic controllers were prospectively treated with ART for 24 weeks. Controllers had a statistically significant decrease in ultrasensitive plasma and rectal HIV RNA levels with ART. Markers of T cell activation/dysfunction in blood and gut mucosa also decreased substantially with ART. Similar reductions were observed in the subset of “elite” controllers with pre-ART plasma HIV RNA levels below conventional assays (<40 copies/mL). These data confirm that HIV replication persists in controllers and contributes to a chronic inflammatory state. ART should be considered for these individuals (ClinicalTrials.gov NCT01025427). [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. The evolving role of plerixafor in hematopoietic progenitor cell mobilization.
- Author
-
Tanhehco, Yvette C., Vogl, Dan T., Stadtmauer, Edward A., and O'Doherty, Una
- Subjects
HODGKIN'S disease ,AUTOTRANSPLANTATION ,PROGENITOR cells ,LYMPHOMAS ,MULTIPLE myeloma ,HEMATOPOIETIC stem cells ,STEM cell transplantation - Abstract
The introduction of plerixafor as a peripheral blood stem cell mobilization agent has allowed more patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's disease to mobilize sufficient hematopoietic progenitor cells ( HPCs) to proceed to autologous transplantation. Because of the high cost of plerixafor, it is not routinely used in all patients undergoing HPC mobilization. If cost were not an issue, an argument could be made that plerixafor could be added to every mobilization regimen, but cost is an issue so in an attempt to be more cost-effective, many centers have limited plerixafor use to patients who have failed or who are predicted to fail collection of adequate numbers of cells by other methods. Additionally, plerixafor is now under investigation both for HPC collection of healthy donors for allogeneic stem cell transplantation and as an adjunct therapy (i.e., chemosensitizing agent) for acute leukemias. This article briefly reviews the role of plerixafor in autologous and allogeneic transplantation as well as its emerging role in the treatment of acute leukemias. Emphasis is placed on the choice of appropriate patients for plerixafor use to assure an adequate stem cell yield while maximizing the cost effectiveness of using plerixafor. The role of prophylactic collections and future areas of research are also presented. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. HIV latency and integration site placement in five cell-based models.
- Author
-
Sherrill-Mix, Scott, Lewinski, Mary K, Famiglietti, Marylinda, Bosque, Alberto, Malani, Nirav, Ocwieja, Karen E, Berry, Charles C, Looney, David, Shan, Liang, Agosto, Luis M, Pace, Matthew J, Siliciano, Robert F, O'Doherty, Una, Guatelli, John, Planelles, Vicente, and Bushman, Frederic D
- Subjects
HIV infections ,ANTIRETROVIRAL agents ,CELL culture ,HIV ,T cells ,MATHEMATICAL models ,GENETICS - Abstract
Background: HIV infection can be treated effectively with antiretroviral agents, but the persistence of a latent reservoir of integrated proviruses prevents eradication of HIV from infected individuals. The chromosomal environment of integrated proviruses has been proposed to influence HIV latency, but the determinants of transcriptional repression have not been fully clarified, and it is unclear whether the same molecular mechanisms drive latency in different cell culture models. Results: Here we compare data from five different in vitro models of latency based on primary human T cells or a T cell line. Cells were infected in vitro and separated into fractions containing proviruses that were either expressed or silent/inducible, and integration site populations sequenced from each. We compared the locations of 6,252 expressed proviruses to those of 6,184 silent/inducible proviruses with respect to 140 forms of genomic annotation, many analyzed over chromosomal intervals of multiple lengths. A regularized logistic regression model linking proviral expression status to genomic features revealed no predictors of latency that performed better than chance, though several genomic features were significantly associated with proviral expression in individual models. Proviruses in the same chromosomal region did tend to share the same expressed or silent/inducible status if they were from the same cell culture model, but not if they were from different models. Conclusions: The silent/inducible phenotype appears to be associated with chromosomal position, but the molecular basis is not fully clarified and may differ among in vitro models of latency. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
14. Gag-Positive Reservoir Cells Are Susceptible to HIV-Specific Cytotoxic T Lymphocyte Mediated Clearance.
- Author
-
Graf, Erin H., Pace, Matthew J., Peterson, Bennett A., Lynch, Lindsay J., Chukwulebe, Steve B., Mexas, Angela M., Shaheen, Farida, Martin, Jeffrey N., Deeks, Steven G., Connors, Mark, Migueles, Stephen A., and O'Doherty, Una
- Subjects
CYTOTOXIC T cells ,ANTIVIRAL agents ,HIV ,T cells ,T helper cells ,MICROBIOLOGY ,IMMUNODEFICIENCY ,IMMUNE response ,IMMUNOPATHOLOGY - Abstract
Resting CD4+T cells infected with HIV persist in the presence of suppressive anti-viral therapy (ART) and are barriers to a cure. One potential curative approach, therapeutic vaccination, is fueled by recognition of the ability of a subset of elite controllers (EC) to control virus without therapy due to robust anti-HIV immune responses. Controllers have low levels of integrated HIV DNA and low levels of replication competent virus, suggesting a small reservoir. As our recent data indicates some reservoir cells can produce HIV proteins (termed GPR cells for Gag-positive reservoir cells), we hypothesized that a fraction of HIV-expressing resting CD4+T cells could be efficiently targeted and cleared in individuals who control HIV via anti-HIV cytotoxic T lymphocytes (CTL). To test this we examined if superinfected resting CD4+T cells from EC express HIV Gag without producing infectious virus and the susceptibility of these cells to CTL. We found that resting CD4+T cells expressed HIV Gag and were cleared by autologous CD8+T cells from EC. Importantly, we found the extent of CTL clearance in our in vitro assay correlates with in vivo reservoir size and that a population of Gag expressing resting CD4+T cells exists in vivo in patients well controlled on therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
15. Quantitation of integrated proviral DNA in viral reservoirs.
- Author
-
Graf, Erin H. and O’Doherty, Una
- Published
- 2013
- Full Text
- View/download PDF
16. Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies.
- Author
-
Eriksson, Susanne, Graf, Erin H., Dahl, Viktor, Strain, Matthew C., Yukl, Steven A., Lysenko, Elena S., Bosch, Ronald J., Jun Lai, Chioma, Stanley, Emad, Fatemeh, Abdel-Mohsen, Mohamed, Hoh, Rebecca, Hecht, Frederick, Hunt, Peter, Ma Somsouk, Wong, Joseph, Johnston, Rowena, Siliciano, Robert F., Richman, Douglas D., and O’Doherty, Una
- Abstract
HIV-1 reservoirs preclude virus eradication in patients receiving highly active antiretroviral therapy (HAART). The best characterized reservoir is a small, difficult-to-quantify pool of resting memory CD4+ T cells carrying latent but replication-competent viral genomes. Because strategies targeting this latent reservoir are now being tested in clinical trials, well-validated high-throughput assays that quantify this reservoir are urgently needed. Here we compare eleven different approaches for quantitating persistent HIV-1 in 30 patients on HAART, using the original viral outgrowth assay for resting CD4+ T cells carrying inducible, replication-competent viral genomes as a standard for comparison. PCR-based assays for cells containing HIV-1 DNA gave infected cell frequencies at least 2 logs higher than the viral outgrowth assay, even in subjects who started HAART during acute/early infection. This difference may reflect defective viral genomes. The ratio of infected cell frequencies determined by viral outgrowth and PCR-based assays varied dramatically between patients. Although strong correlations with the viral outgrowth assay could not be formally excluded for most assays, correlations achieved statistical significance only for integrated HIV-1 DNA in peripheral blood mononuclear cells and HIV-1 RNA/DNA ratio in rectal CD4+ T cells. Residual viremia was below the limit of detection in many subjects and did not correlate with the viral outgrowth assays. The dramatic differences in infected cell frequencies and the lack of a precise correlation between culture and PCR-based assays raise the possibility that the successful clearance of latently infected cells may be masked by a larger and variable pool of cells with defective proviruses. These defective proviruses are detected by PCR but may not be affected by reactivation strategies and may not require eradication to accomplish an effective cure. A molecular understanding of the discrepancy between infected cell frequencies measured by viral outgrowth versus PCR assays is an urgent priority in HIV-1 cure research. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
17. Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration.
- Author
-
Azzoni, Livio, Foulkes, Andrea S., Papasavvas, Emmanouil, Mexas, Angela M., Lynn, Kenneth M., Mounzer, Karam, Tebas, Pablo, Jacobson, Jeffrey M., Frank, Ian, Busch, Michael P., Deeks, Steven G., Carrington, Mary, O'Doherty, Una, Kostman, Jay, and Montaner, Luis J.
- Subjects
HIV infections ,THERAPEUTICS ,INTERFERONS ,ANTIRETROVIRAL agents ,IMMUNE system ,VIRAL replication ,IMMUNOTHERAPY ,MEDICAL statistics - Abstract
Background. Antiretroviral therapy (ART)–mediated immune reconstitution fails to restore the capacity of the immune system to spontaneously control human immunodeficiency virus (HIV) replication.Methods. A total of 23 HIV type 1 (HIV-1)–infected, virologically suppressed subjects receiving ART (CD4+ T-cell count, >450 cells/μL) were randomly assigned to have 180 μg/week (for arm A) or 90 μg/week (for arm B) of pegylated (Peg) interferon alfa-2a added to their current ART regimen. After 5 weeks, ART was interrupted, and Peg–interferon alfa-2a was continued for up to 12 weeks (the primary end point), with an option to continue to 24 weeks. End points included virologic failure (viral load, ≥400 copies/mL) and adverse events. Residual viral load and HIV-1 DNA integration were also assessed.Results. At week 12 of Peg–interferon alfa-2a monotherapy, viral suppression was observed in 9 of 20 subjects (45%), a significantly greater proportion than expected (arm A, P = .0088; arm B, P = .0010; combined arms, P < .0001). Over 24 weeks, both arms had lower proportions of subjects who had viral load, compared with the proportion of subjects in a historical control group (arm A, P = .0046; arm B, P = .0011). Subjects who had a sustained viral load of <400 copies/mL had decreased levels of integrated HIV DNA (P = .0313) but increased residual viral loads (P = .0078), compared with subjects who experienced end-point failure.Conclusions. Peg–interferon alfa-2a immunotherapy resulted in control of HIV replication and decreased HIV-1 integration, supporting a role for immunomediated approaches in HIV suppression and/or eradication.Clinical Trials Registration. NCT00594880. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
18. American society for apheresis white paper: Considerations for medical staff apheresis medicine physician credentialing and privileging.
- Author
-
Andrzejewski,, Chester, Linz, Walter, Hofmann, Jan, O'Doherty, Una, Robinson, Richard S., Arepally, Gowthami M., and Golden, Patricia
- Abstract
Introduction: Physician supervision of apheresis contributes to safe and high-quality patient care. Literature is limited regarding the requirements for hospital privileges of physicians providing apheresis services. This report provides recommendations from the American Society for Apheresis (ASFA) regarding this topic. Materials and Methods: The ASFA Public Affairs Committee was charged by the society's Board of Directors (BOD) to work collaboratively with other ASFA committees to develop guidance pertaining to requirements for hospital privileges of physicians in apheresis medicine. After review of the literature and discussions with members from diverse practice environments, draft guidance was created and circulated among pertinent parties for comment and revision. The final document, approved by the BOD in 2011, is presented herein. Results: Assurance of patient safety was the paramount focus in the deliberations. Establishment and maintenance of physician competency in the discipline of apheresis medicine, and the documentation thereof, were consensus priorities. The importance of care teams involving non-physicians and the support structures within hospitals were also identified as other important contributors to patient safety. Conclusion: Patient safety during therapeutic apheresis involves both practitioners' and institutional provision of care aspects. Physician training experiences, medical licensing, and board certification status, along with continuing medical education and participation in risk management/patient safety projects are characteristic facets of physician competency in the provision of quality apheresis medicine interventions. Documentation of such indicators may help in medical staff deliberations regarding physician privileging in the oversight and management of apheresis medicine activities in hospitals. J. Clin. Apheresis, 2012. © 2012 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
19. Directly Infected Resting CD4+T Cells Can Produce HIV Gag without Spreading Infection in a Model of HIV Latency.
- Author
-
Pace, Matthew J., Graf, Erin H., Agosto, Luis M., Mexas, Angela M., Male, Frances, Brady, Troy, Bushman, Frederic D., and O'Doherty, Una
- Subjects
HIV infections ,THERAPEUTICS ,HIGHLY active antiretroviral therapy ,CD4 antigen ,T cells ,IMMUNE response - Abstract
Despite the effectiveness of highly active antiretroviral therapy (HAART) in treating individuals infected with HIV, HAART is not a cure. A latent reservoir, composed mainly of resting CD4+T cells, drives viral rebound once therapy is stopped. Understanding the formation and maintenance of latently infected cells could provide clues to eradicating this reservoir. However, there have been discrepancies regarding the susceptibility of resting cells to HIV infection in vitro and in vivo. As we have previously shown that resting CD4+T cells are susceptible to HIV integration, we asked whether these cells were capable of producing viral proteins and if so, why resting cells were incapable of supporting productive infection. To answer this question, we spinoculated resting CD4+T cells with or without prior stimulation, and measured integration, transcription, and translation of viral proteins. We found that resting cells were capable of producing HIV Gag without supporting spreading infection. This block corresponded with low HIV envelope levels both at the level of protein and RNA and was not an artifact of spinoculation. The defect was reversed upon stimulation with IL-7 or CD3/28 beads. Thus, a population of latent cells can produce viral proteins without resulting in spreading infection. These results have implications for therapies targeting the latent reservoir and suggest that some latent cells could be cleared by a robust immune response. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
20. Elite Suppressors Harbor Low Levels of Integrated HIV DNA and High Levels of 2-LTR Circular HIV DNA Compared to HIV+ Patients On and Off HAART.
- Author
-
Graf, Erin H., Mexas, Angela M., Yu, Jianqing J., Shaheen, Farida, Liszewski, Megan K., Di Mascio, Michele, Migueles, Stephen A., Connors, Mark, and O'Doherty, Una
- Subjects
HIV-positive persons ,HIV infections ,HIGHLY active antiretroviral therapy ,CELL physiology ,MEDICAL care ,VIRAL disease prevention - Published
- 2011
- Full Text
- View/download PDF
21. Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.
- Author
-
Tanhehco, Yvette C., Adamski, Jill, Sell, Mary, Cunningham, Kathleen, Eisenmann, Christa, Magee, Deborah, Stadtmauer, Edward A., and O'Doherty, Una
- Abstract
Background: Plerixafor (Mozobil, AMD3100) with granulocyte-colony stimulating factor (G-CSF) mobilizes more CD34+ cells/kg compared to G-CSF alone. Given that plerixafor enhances mobilization of multiple white blood cell lineages, we determined if more storage space is required for products collected from patients mobilized with plerixafor. Methods: A review of the medical records of 15 patients mobilized with chemotherapy and G-CSF (control) and 14 patients mobilized with plerixafor plus G-CSF (plerixafor) was performed. Data on demographics, baseline characteristics, CD34+ cells/kg, total nucleated cells, total mononuclear cells, total apheresis sessions, and total bags for storage were collected. Mean values were determined and compared using Student's t-test. Results: We found that the proportion of CD34+ cells among total nucleated cells was less in the plerixafor group compared to the control group ( P = 0.0427). More nucleated cells (10.7 × 10
10 vs. 7.1 × 1010 , P =0.0452) and mononuclear cells (9.7 × 1010 vs. 5.9 × 1010 , P = 0.0059) were mobilized with plerixafor plus G-CSF. However, there was no significant difference in CD34+ cells/kg, total CD34+ cells or the proportion of mononuclear cells among total nucleated cells between the two groups. More storage bags were required for the plerixafor group compared to the control group (15 vs. 9, P = 0.0299). Conclusion: Mobilization with plerixafor plus G-CSF resulted in a smaller proportion of CD34+ cells collected and a greater number of storage bags. An increase in the number of bags required for stem cell storage may be logistically problematic and will also lead to increased costs for storage of stem cells. J. Clin. Apheresis 25:202-208, 2010. © 2010 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
22. Genetic Evidence That Naive T Cells Can Contribute Significantly to the Human Immunodeficiency Virus Intact Reservoir: Time to Re-evaluate Their Role.
- Author
-
Rullo, Emmanuele Venanzi, Cannon, LaMont, Pinzone, Marilia Rita, Ceccarelli, Manuela, Nunnari, Giuseppe, and O'Doherty, Una
- Subjects
GENETICS ,HIV ,T cells - Published
- 2019
- Full Text
- View/download PDF
23. Mechanisms of human immunodeficiency virus-1 latency.
- Author
-
O'Doherty, Una
- Subjects
IMMUNE response ,ANTIVIRAL agents ,ANTIRETROVIRAL agents ,HIV infections ,VIROLOGY - Abstract
Discusses the mechanisms of HIV-1 for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Presentation on the importance of an vitro model of HIV-1 latency; Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection; Measurements of various steps in the viral life cycle.
- Published
- 2005
- Full Text
- View/download PDF
24. Long HIV Type 1 Reverse Transcripts Can Accumulate Stably within Resting CD4+ T Cells While Short Ones Are Degraded.
- Author
-
Swiggard, William J., O'Doherty, Una, McGain, David, Jeyakumar, Deepa, and Malim, Michael H.
- Published
- 2004
25. Dendritic cells from skin and blood of macaques both promote SIV replication with T cells from different anatomical sites.
- Author
-
Ignatius, Ralf, Isdell, Frank, O'Doherty, Una, and Pope, Melissa
- Subjects
MACAQUES ,DENDRITIC cells - Abstract
The SIV-macaque system offers the opportunity to study the pathogenesis and immune aspects of a primate retroviral infection in which immunodeficiency also develops, much like HIV infection in humans. Since it is known that human dendritic cells (DCs) am involved in HIV replication, mature cytokine-generated DCs obtained from precursors in the blood and skin-derived DCs were isolated from healthy rhesus macaques and compared with respect to their ability to support SIV infection. Here, it is shown for both skin- and blood-derived DCs that i) virus production depends on both DCs and T cells, ii) this occurs similarly with T cells from blood, skin, spleen, or lymph nodes, and iii) DCs can transmit virus equally to syngeneic and allogeneic T cells. No differences between DCs from skin or blood were observed. Therefore, the easily accessible blood-derived DCs of macaques provide an appropriate population to study the role of DCs in immunodeficiency virus infection. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
26. Hematopoietic Stem Cells and HIV Infection.
- Author
-
Pace, Matthew and O'Doherty, Una
- Subjects
HEMATOPOIETIC stem cells ,HIV infections ,GLYCOPROTEINS ,PROGENITOR cells ,T cells - Abstract
The article discusses the research work done by McNamara et al to determine whether hematopoietic stem cells or progenitor cells (HSCs) are infected by human immunodeficiency virus (HIV) infection in vivo. It informs that McNamara has selected some immature HSCs by using human glycoprotein CD133 to perform his experiment. It mentions that the in vivo data suggests that HSC infection occurs in a subset of patients and do not cause T-cell contamination.
- Published
- 2013
- Full Text
- View/download PDF
27. Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion.
- Author
-
Pinzone, Marilia Rita, VanBelzen, D. Jake, Weissman, Sam, Bertuccio, Maria Paola, Cannon, LaMont, Venanzi-Rullo, Emmanuele, Migueles, Stephen, Jones, R. Brad, Mota, Talia, Joseph, Sarah B., Groen, Kevin, Pasternak, Alexander O., Hwang, Wei-Ting, Sherman, Brad, Vourekas, Anastasios, Nunnari, Giuseppe, and O'Doherty, Una
- Abstract
After initiating antiretroviral therapy (ART), a rapid decline in HIV viral load is followed by a long period of undetectable viremia. Viral outgrowth assay suggests the reservoir continues to decline slowly. Here, we use full-length sequencing to longitudinally study the proviral landscape of four subjects on ART to investigate the selective pressures influencing the dynamics of the treatment-resistant HIV reservoir. We find intact and defective proviruses that contain genetic elements favoring efficient protein expression decrease over time. Moreover, proviruses that lack these genetic elements, yet contain strong donor splice sequences, increase relatively to other defective proviruses, especially among clones. Our work suggests that HIV expression occurs to a significant extent during ART and results in HIV clearance, but this is obscured by the expansion of proviral clones. Paradoxically, clonal expansion may also be enhanced by HIV expression that leads to splicing between HIV donor splice sites and downstream human exons. How HIV reservoirs are shaped over time on antiviral therapy is poorly understood. Here, the authors analyze the dynamics of the HIV reservoir by longitudinal proviral sequencing revealing that HIV reservoir expression can contribute to its clearance and paradoxically even to its persistence. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
28. Measuring integrated HIV DNA ex vivo and in vitro provides insights about how reservoirs are formed and maintained.
- Author
-
Pinzone, Marilia Rita and O’Doherty, Una
- Subjects
HIGHLY active antiretroviral therapy ,HIV ,HIV infections ,VIRAL replication ,VIRAL load - Abstract
The identification of the most appropriate marker to measure reservoir size has been a great challenge for the HIV field. Quantitative viral outgrowth assay (QVOA), the reference standard to quantify the amount of replication-competent virus, has several limitations, as it is laborious, expensive, and unable to robustly reactivate every single integrated provirus. PCR-based assays have been developed as an easier, cheaper and less error-prone alternative to QVOA, but also have limitations. Historically, measuring integrated HIV DNA has provided insights about how reservoirs are formed and maintained. In the 1990s, measuring integrated HIV DNA was instrumental in understanding that a subset of resting CD4 T cells containing integrated HIV DNA were the major source of replication-competent virus. Follow-up studies have further characterized the phenotype of these cells containing integrated HIV DNA, as well as shown the correlation between the integration levels and clinical parameters, such as duration of infection, CD4 count and viral load. Integrated HIV DNA correlates with total HIV measures and with QVOA. The integration assay has several limitations. First, it largely overestimates the reservoir size, as both defective and replication-competent proviruses are detected. Since defective proviruses are the majority in patients on ART, it follows that the number of proviruses capable of reactivating and releasing new virions is significantly smaller than the number of integrated proviruses. Second, in patients on ART clonal expansion could theoretically lead to the preferential amplification of proviruses close to an
Alu sequence though longitudinal studies have not captured this effect. Proviral sequencing combined with integration measures is probably the best estimate of reservoir size, but it is expensive, time-consuming and requires considerable bioinformatics expertise. All these reasons limit its use on a large scale. Herein, we review the utility of measuring HIV integration and suggest combining it with sequencing and total HIV measurements can provide insights that underlie reservoir maintenance. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
29. Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs.
- Author
-
Baxter, Amy E., O’Doherty, Una, and Kaufmann, Daniel E.
- Subjects
HIV infections ,VIRAL replication ,MESSENGER RNA ,VIRAL receptors ,CD4 antigen ,FLOW cytometry ,FLUORESCENCE in situ hybridization - Abstract
Recent years have seen a substantial increase in the number of tools available to monitor and study HIV reservoirs. Here, we discuss recent technological advances that enable an understanding of reservoir dynamics beyond classical assays to measure the frequency of cells containing provirus able to propagate a spreading infection (replication-competent reservoir). Specifically, we focus on the characterization of cellular reservoirs containing proviruses able to transcribe viral mRNAs (so called transcription-competent) and translate viral proteins (translation-competent). We suggest that the study of these alternative reservoirs provides complementary information to classical approaches, crucially at a single-cell level. This enables an in-depth characterization of the cellular reservoir, both following reactivation from latency and, importantly, directly ex vivo at baseline. Furthermore, we propose that the study of cellular reservoirs that may not contain fully replication-competent virus, but are able to produce HIV mRNAs and proteins, is of biological importance. Lastly, we detail some of the key contributions that the study of these transcription and translation-competent reservoirs has made thus far to investigations into HIV persistence, and outline where these approaches may take the field next. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur Wiesch and van Lunzen.
- Author
-
Azzoni, Livio, Foulkes, Andrea S, Papasavvas, Emmanouil, Mexas, Angela M, Lynn, Kenneth M, Mounzer, Karam, Tebas, Pablo, Jacobson, Jeffrey M, Frank, Ian, O'Doherty, Una, Kostman, Jay, and Montaner, Luis J
- Published
- 2013
- Full Text
- View/download PDF
31. Reply to zur Wiesch and van Lunzen.
- Author
-
Azzoni, Livio, Foulkes, Andrea S., Papasavvas, Emmanouil, Mexas, Angela M., Lynn, Kenneth M., Mounzer, Karam, Tebas, Pablo, Jacobson, Jeffrey M., Frank, Ian, O'Doherty, Una, Kostman, Jay, and Montaner, Luis J.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.